SAN DIEGO — HemOnc Today Editorial Board member Kanti R. Rai, MD, professor of medicine at Zucker School of Medicine at Hofstra/Northwell, reviews a late-breaking abstract presented at the ASH Annual Meeting and Exposition that examined the safety and efficacy of ibrutinib plus rituximab in treatment-naive patients with chronic lymphocytic leukemia.
The phase 3 trial showed that ibrutinib (Imbruvica; Pharmacyclics, Janssen) plus rituximab (Rituxan; Genentech, Biogen) prolonged PFS (HR = 0.35; 95% CI, 0.22-0.55) and OS (HR = 0.16; 95% CI, 0.05-0.54) compared with standard chemoimmunotherapy.
“The presenters believe that these results will be game changers,” Rai says. “I think it is a major step forward in the treatment of previously untreated CLL patients.”
Shanafelt TD, et al. Abstract LBA-4. Presented at: ASH Annual Meeting and Exposition; Dec. 1-4, 2018; San Diego.
Disclosure: Rai reports no relevant financial disclosures.